title: Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.
abstract: MYCN amplification in neuroblastoma is usually associated with a poor prognosis. Very few cases of heterogenous MYCN amplification have been previously reported, and the clinical significance of heterogeneity is unclear. We report a neonate with an adrenal stage 4S neuroblastoma with a small focus of MYCN-amplified cells within a nonamplified background. After adrenalectomy, the patient has been observed without use of chemotherapy and has no evidence of disease progression.
authors.affiliation: *Division of Hematology/Oncology †Division of Pathology §Department of Radiology ∥Division of Gastroenterology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH ‡Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Bishop
authors.forename: Hong
authors.initials: H
authors.lastname: Yin
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Shimada
authors.forename: Alexander J
authors.initials: AJ
authors.lastname: Towbin
authors.forename: Alexander
authors.initials: A
authors.lastname: Miethke
authors.forename: Brian
authors.initials: B
authors.lastname: Weiss
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000235:genetics / Q000473:pathology / Q000628:therapy; D008113:Liver Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008297:Male; D000071447:N-Myc Proto-Oncogene Protein; D009447:Neuroblastoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D009687:Nuclear Proteins / Q000235:genetics*; D015513:Oncogene Proteins / Q000235:genetics*; D011379:Prognosis
chemical_list: C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins